Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 6.7% – Time to Sell?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) traded down 6.7% during mid-day trading on Monday . The stock traded as low as $9.54 and last traded at $9.54. 61,636 shares were traded during mid-day trading, an increase of 74% from the average session volume of 35,474 shares. The stock had previously closed at $10.22.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $38.00 price target on shares of Greenwich LifeSciences in a report on Tuesday, February 11th.

Greenwich LifeSciences Price Performance

The stock has a market cap of $122.91 million, a PE ratio of -11.69 and a beta of 1.69. The company has a 50 day moving average price of $11.95 and a two-hundred day moving average price of $12.89.

Insider Buying and Selling at Greenwich LifeSciences

In related news, CEO Snehal Patel acquired 2,500 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was purchased at an average cost of $12.51 per share, with a total value of $31,275.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,552,502 shares of the company’s stock, valued at approximately $69,461,800.02. This trade represents a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have purchased 6,300 shares of company stock worth $79,965. Company insiders own 51.67% of the company’s stock.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of large investors have recently added to or reduced their stakes in GLSI. Geode Capital Management LLC boosted its stake in shares of Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after buying an additional 5,861 shares during the last quarter. Northern Trust Corp lifted its holdings in Greenwich LifeSciences by 17.3% in the fourth quarter. Northern Trust Corp now owns 87,423 shares of the company’s stock valued at $982,000 after acquiring an additional 12,923 shares during the period. State Street Corp boosted its position in Greenwich LifeSciences by 4.4% in the third quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after purchasing an additional 3,005 shares during the last quarter. Garden State Investment Advisory Services LLC bought a new stake in shares of Greenwich LifeSciences during the 3rd quarter valued at about $253,000. Finally, Barclays PLC increased its position in shares of Greenwich LifeSciences by 12.7% during the 4th quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after purchasing an additional 1,088 shares during the last quarter. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.